Farma

inva
14.02.2021 kl 20:10 889

Outlook Q4 presentation 2020

Summary and outlook

Building a leading Nordic pharma company targeting growth in
Northern Europe

In Q3 2020, we have
• Strengthened the core by driving underlying growth in the existing portfolio
• Launched ThermaCare® with ramp-up of revenues during the quarter
• Included the acquired portfolio of antibiotics for hospital use, and started onboarding of
revenues

We will build on our solid foundation and
• Strengthen the existing business by leveraging our highly scalable market access
platform
• Launch new products in at least one country in each launch window going forward
• Increase value by acquiring and strengthening own products and brands

…targeting 20% annual organic growth from 2021, and a mid- to long-term ambition of
building a 500 MNOK company with a gross margin of 40% and an EBITDA margin of 15%

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.